Literature DB >> 17726699

Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.

Timon P H Buys1, Raj Chari, Eric H L Lee, May Zhang, Calum MacAulay, Stephen Lam, Wan L Lam, Victor Ling.   

Abstract

The multidrug resistant (MDR) phenotype is often attributed to the activity of ATP-binding cassette (ABC) transporters such as P-glycoprotein (ABCB1). Previous work has suggested that modulation of MDR may not necessarily be a single gene trait. To identify factors that contribute to the emergence of MDR, we undertook integrative genomics analysis of the ovarian carcinoma cell line SKOV3 and a series of MDR derivatives of this line (SKVCRs). As resistance increased, comparative analysis of gene expression showed conspicuous activation of a network of genes in addition to ABCB1. Functional annotation and pathway analysis revealed that many of these genes were associated with the extracellular matrix and had previously been implicated in tumor invasion and cell proliferation. Further investigation by whole genome tiling-path array CGH suggested that changes in gene dosage were key to the activation of several of these overexpressed genes. Remarkably, alignment of whole genome profiles for SKVCR lines revealed the emergence and decline of specific segmental DNA alterations. The most prominent alteration was a novel amplicon residing at 16p13 that encompassed the ABC transporter genes ABCC1 and ABCC6. Loss of this amplicon in highly resistant SKVCR lines coincided with the emergence of a different amplicon at 7q21.12, which harbors ABCB1. Integrative analysis suggests that multiple genes are activated during escalation of drug resistance, including a succession of ABC transporter genes and genes that may act synergistically with ABCB1. These results suggest that evolution of the MDR phenotype is a dynamic, multi-genic process in the genomes of cancer cells. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726699     DOI: 10.1002/gcc.20492

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

Review 1.  ABCC6 as a target in pseudoxanthoma elasticum.

Authors:  András Váradi; Zalán Szabó; Viola Pomozi; Hugues de Boussac; Krisztina Fülöp; Tamás Arányi
Journal:  Curr Drug Targets       Date:  2011-05       Impact factor: 3.465

Review 2.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

3.  Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.

Authors:  Carin K Ingemarsdotter; Laura A Tookman; Ashley Browne; Katrina Pirlo; Rosalind Cutts; Claude Chelela; Karisma F Khurrum; Elaine Y L Leung; Suzanne Dowson; Lee Webber; Iftekhar Khan; Darren Ennis; Nelofer Syed; Tim R Crook; James D Brenton; Michelle Lockley; Iain A McNeish
Journal:  Mol Oncol       Date:  2014-12-29       Impact factor: 6.603

Review 4.  PPEF/PP7 protein Ser/Thr phosphatases.

Authors:  Alexandra V Andreeva; Mikhail A Kutuzov
Journal:  Cell Mol Life Sci       Date:  2009-08-07       Impact factor: 9.261

5.  Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.

Authors:  Lara Milane; Zhenfeng Duan; Mansoor Amiji
Journal:  Mol Pharm       Date:  2010-11-24       Impact factor: 4.939

6.  Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.

Authors:  Ai-Chung Mar; Chun-Ho Chu; Hui-Ju Lee; Chia-Wen Chien; Jing-Jy Cheng; Shung-Haur Yang; Jeng-Kai Jiang; Te-Chang Lee
Journal:  J Biol Chem       Date:  2015-07-24       Impact factor: 5.157

7.  Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.

Authors:  Shelley B Hooks; Phillip Callihan; Molly K Altman; Jillian H Hurst; Mourad W Ali; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-11-02       Impact factor: 27.401

8.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31

9.  Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer.

Authors:  Zhenfeng Duan; Edward J Weinstein; Diana Ji; Rachel Y Ames; Edwin Choy; Henry Mankin; Francis J Hornicek
Journal:  Mol Cancer Ther       Date:  2008-08-07       Impact factor: 6.261

Review 10.  Multi-functional nanocarriers to overcome tumor drug resistance.

Authors:  Lara S Jabr-Milane; Lilian E van Vlerken; Sunita Yadav; Mansoor M Amiji
Journal:  Cancer Treat Rev       Date:  2008-06-05       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.